Navigation Links
BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
Date:2/29/2012

LYNBROOK, N.Y., Feb. 29, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences during the month of March 2012.

  • Cowen and Company 32nd Annual Health Care Conference (Boston, MA)
    Wednesday, March 7, 2012 at 10:40 a.m. EST
  • ROTH Capital Partners 24th Annual Conference (Laguna Niguel, CA)
    Tuesday, March 13, 2012 at 3:30 p.m. PDT (6:30 p.m. EDT)

The live webcasts of these presentations can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with a palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase 3 pivotal clinical trials, as well as for Frozen Shoulder (Adhesive Capsulitis) and cellulite which are in Phase 2 and Phase 1 respectively. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupuytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals has the development, supply and commercialization rights in Canada, Australia, Brazil and Mexico. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2011 Financial Results on November 8, 2011
3. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
4. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
5. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
6. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2010 Financial Results on March 11, 2011
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
8. BioSpecifics Announces Positive Results From Clinical Trial in Canine Lipomas
9. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
10. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
11. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... Vertebral Technologies, Inc., announces the successful outcome of the first lumbar fusion ... VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical ...
(Date:1/12/2017)... Colo (PRWEB) , ... January 12, 2017 , ... ... then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few ... describes a new drug combination that has stabilized Rosendahl’s disease and increased both ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 The report "Direct-Fed ... Aquatic Animals), Form (Dry and Liquid), and Region - Global Forecast to 2022", ... 934.5 Million in 2016 and projected to reach USD 1,399.6 Million by 2022, ... Reading ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell , ... technology, and STMicroelectronics (NYSE: STM), a global ... electronics applications, announced today the launch of a ... biometric wearables that includes ST,s compact SensorTile ... Benchmark™ biometric sensor system. Together, SensorTile and ...
(Date:12/16/2016)... 16, 2016   IdentyTechSolutions America LLC , ... and solutions and a cutting-edge manufacturer of software ... is offering seamless, integrated solutions that comprise IDT ... The solutions provide IdentyTech,s customers with combined physical ... from crime and theft. "We are ...
(Date:12/16/2016)... Dec. 16, 2016 The global wearable medical device market, ... by 2021 from USD 5.31 billion in 2016, at a CAGR ... ... by technological advancements in medical devices, launch of a growing number ... wireless connectivity among healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):